Table 1.
Clinical and pathological characteristics of study patients.
| Characteristic | Cancer | No cancer | P-value |
|---|---|---|---|
| No. (%) | 338 (34) | 654 (66) | |
| Age (years) | |||
| Mean ± SD | 67.9 ± 6.9 | 65.4 ± 6.9 | < 0.001 |
| Range | 45–84 | 47–89 | |
| Median (IQR) | 68 (63–73) | 66 (61–70) | |
| Suspicious DRE (%) | 28 (8.3) | 26 (4) | 0.007 |
| PSA (ng/ml) | |||
| Mean ± SD | 8.02 ± 4.06 | 6.60 ± 2.83 | < 0.001 |
| Range | 1.2–20 | 0.4–19 | |
| Median (IQR) | 6.8 (5.2–9.5) | 5.9 (4.9–7.8) | |
| Prostate volume (ml) | |||
| Mean ± SD | 37.90 ± 22.6 | 53.46 ± 25.30 | < 0.001 |
| Range | 10–198 | 10–190 | |
| Median (IQR) | 32.5 (23–46) | 49 (36–65) | |
| PSAD (ng/ml2) | |||
| Mean ± SD | 0.27 ± 0.2 | 0.14 ± 0.1 | < 0.001 |
| Range | 0.04–1.33 | 0.006–1.50 | |
| Median (IQR) | 0.21 (0.14–0.34) | 0.12 (0.09–0.17) | |
| Prostate cancer histology | |||
| ISUP grade group | (%) | ||
| 1 | 49.8 | ||
| 2 | 21.6 | ||
| 3 | 6.6 | ||
| 4 | 15.4 | ||
| 5 | 6.6 | ||
| Clinical stage | (%) | ||
| T1c | 69 | ||
| T2a | 24 | ||
| T2b | 2 | ||
| T2c | 4 | ||
| T3a | 1 | ||
PSA, prostate-specific antigen; PSAD, PSA density; ISUP, international society of urological pathology. SD, Standard deviation; IQR, interquartile range.